Association between depression symptom severity and total cost of care: Findings from a large, 2-year, claims-based, retrospective population health study

AA Popkov, TS Barrett, A Shergill, M Donohue… - Journal of Affective …, 2025 - Elsevier
Background Despite the substantial impact of depression on individuals and healthcare
utilization, little is known about the specific relationship between depression severity and …

Lithium: how low can you go?

R Strawbridge, AH Young - International Journal of Bipolar Disorders, 2024 - Springer
Page 2 of 6 Strawbridge and Young International Journal of Bipolar Disorders (2024) 12: 4
and for a short period of time (Goodwin et al. 2016). Support for high-dose lithium is also …

Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review

N Chisamore, E Kaczmarek, GH Le, S Wong… - … Treatment Options in …, 2024 - Springer
Abstract Purpose of Review Serotonergic psychedelics include psilocybin, lysergic acid
diethylamide (LSD), dimethyltryptamine (DMT), and other agonists of the 5-HT2A receptor …

[PDF][PDF] Prescription réfléchie pour les patients souffrant d'une dépression difficile à traiter

A Soubolsky, J Visentin, A Crawley - Canadian Family Physician, 2023 - cfp.ca
Amy Soubolsky BSP MSc Jessica Visentin PharmD ACPR Alex Crawley BSP ACPR Le
trouble dépressif majeur est très courant. Chaque année, environ 1 Canadien sur 20 en …

[HTML][HTML] Peripheral inflammatory effects of different interventions for treatment-resistant depression: a systematic review

R Strawbridge, E Izurieta, E Day, H Tee, K Young… - Neuroscience …, 2023 - Elsevier
Background Immune-related mechanisms are increasingly recognised as important in the
pathophysiology of depression, particularly treatment-resistant depression (TRD) …

The downstaging concept in treatment-resistant depression: spotlight on ketamine

A Wilkowska, WJ Cubała - International Journal of Molecular Sciences, 2022 - mdpi.com
Treatment-resistant depression is a pleomorphic phenomenon occurring in 30% of patients
with depression. The chance to achieve remission decreases with every subsequent …

Amygdala subregional functional connectivity in Treatment-Resistant Depression

SL Foster, R Landin-Romero, S Lewis, AR Barreiros… - medRxiv, 2024 - medrxiv.org
Background: Treatment resistance impacts almost 50% of depression patients, with
amygdala dysfunction being widely implicated. The amygdala is a complex amalgamation of …

[HTML][HTML] Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior …

S Bhattacharyya, S MahmoudianDehkordi… - medRxiv, 2024 - ncbi.nlm.nih.gov
Metabolomics provides powerful tools that can inform about heterogeneity in disease and
response to treatments. In this study, we employed an electrochemistry-based targeted …

Unipolar depression

CF Gillespie, CB Nemeroff - Rosenberg's Molecular and Genetic Basis of …, 2025 - Elsevier
Unipolar depressive disorder, also known as major depressive disorder, is a
heterogeneous, environmentally influenced, and genetically complex psychiatric disorder …

Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort …

S Pappa, M Shah, S Young, T Anwar, T Ming - BJPsych open, 2024 - cambridge.org
BackgroundDespite the availability of effective therapies, many patients with major
depressive disorder (MDD) develop treatment-resistant depression (TRD). AimsTo evaluate …